- With the wheeze of the bagpipes and a glimpse of Durie knee
Scotland came to Los Angeles for the 14th Anniversary Ribbon of Hope Gala. Guest of honor was the IMF's own Dr. Brian G.M. Durie. Also honored for their contributions to the myeloma community were
- Controversies in Myeloma Management
The IMF and the Institute for Continuing Healthcare Education will sponsor a Corporate Friday Symposium preceding the 46th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The CME-certified symposium will be held December 3, 2004, at 6:00 p.m.
- Dr. Durie to speak on "Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation with Aredia® and Zometa® Use" at the annual meeting of the American Society of Hematology.
Tuesday, December 7, 2004 at 8:30 a.m.
- MAY WE HAVE THE ENVELOPE, PLEASE!
The 2004 IMF direct-mail campaign will be in your mailbox soon. In the past, your contributions have helped the IMF fund research, staff the Hotline, put on Patient & Family Seminars, conduct the osteonecrosis survey, and develop BANK ON A CURE®, the first DNA bank dedicated to myeloma research. Please continue to support our efforts to educate, treat, and promote research that leads to breakthroughs in myeloma care. You can contribute online here, or send us your contribution in the envelope soon to arrive!
- Tokyo Patient & Family Seminar attended by over 300.
It was their most successful to date.
- San Diego Patient & Family Seminar a Sold Out Success
From the moving presentation by Gerry Difford on Friday night to the breakout seminars with the experts where each participant was able to ask specific questions about his or her course of treatment, this seminar was right on.
- Kosan Enters KOS-953 and VELCADE® Combination Into Clinic
Kosan Biosciences has initiated a company- sponsored Phase Ib clinical trial to investigate KOS-953 (17-AAG) in combination with VELCADE®.
- Cancer care for the elderly gets refined
Many older patients who in the past might have been denied treatment because of their advanced age are now being given life-prolonging regimens. At the same time, frailer patients with slow-growing cancer are often being allowed to live out their lives without aggressive, toxic treatment.
- IMFer Tom Callaghan to be featured guest on a special live segment on Balloon Kyphoplasty on American Health Radio
Based in the Chicago area, WRMN AM 1410's American Health Radio has over 3 million listeners and is one of the longest running health and fitness shows in the country. Tom will appear with Richard Mott, president and CEO of Kyphon. You can listen to the show on the radio or on the web (click on WRMN Internet Radio) December 6, from 6:00 - 7:00 pm CST. Broadcast will be repeated December 8 from 8:00 - 9:00 pm CST and December 10 from 6:00 - 7:00 pm CST.
WHAT'S NEW IN RESEARCH
- VELCADE® trials
- THALOMID® trials
- TRISENOX_ trials
- REVLIMID trials
- DOXIL trials
- Canadian VELCADE® trial.
A study is currently underway in Canada in patients that have relapsed or are refractory to at least 2 lines of chemotherapy for multiple myeloma. The trial is open, or in the process of being opened, in at least one cancer centre or hospital in every province of the country with the exception of PEI and Newfoundland. If a patient is interested in obtaining more information about the trial, they should discuss it with their oncologist or treating physician. The oncologist or treating physician will then refer the patient to the nearest trial center. If the physician is not aware of the nearest trial center then he/she should contact Ortho Biotech at 416-382-4911. Ortho Biotech will contact the trial center and request permission for the physician to contact that site with regards to a patient referral.
- Multi-center, randomized, controlled Phase III study to evaluate safety and efficacy of NeoRx's Skeletal Targeted Radiotherapy (STR) plus Melphalan to Melphalan Alone, with Stem Cell Transplant in Multiple Myeloma.
For more information, the Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find CenterWatch and EmergingMed. The IMF has entered into partnerships with them to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
It's that time again. This year why not give a gift that gives twice? Shop in our boutique and the IMF receives a portion (and sometimes all the proceeds) of each sale.
- Ever think of walking or running a marathon?
Join the IMF Team Milers Against Myeloma and help raise awareness and dollars for cancer research at the Rock ‘n’ Roll Marathon on June 5, 2005 in San Diego, California. If interested in joining Team Milers Against Myeloma, email Candace McDonald, Associate Director of Development at email@example.com.
- Volume II of Cooking with the IMF
The collection of recipes for Volume II of our very popular healthy food cookbook is being led by Marilyn Alexander, a myeloma survivor from Philadelphia. Please help us with this important project by submitting your favorite recipes.
ITEMS OF INTEREST
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Tax-deductible donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.